This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marques, A. R.
Right arrow Articles by Philipp, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marques, A. R.
Right arrow Articles by Philipp, M. T.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2002, p. 2591-2593, Vol. 40, No. 7
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.7.2591-2593.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine

Adriana R. Marques,1* Dale S. Martin,2 and Mario T. Philipp2

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,1 Tulane Regional Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana2

Received 3 December 2001/ Returned for modification 9 March 2002/ Accepted 1 April 2002

The C6 enzyme-linked immunosorbent assay (ELISA), based on a peptide (C6) that reproduces the sequence of invariable region 6 of VlsE, the antigenic variation protein of Borrelia burgdorferi, has been shown to be a sensitive and specific test for the serologic diagnosis of Lyme disease. We now report that none of 29 uninfected individuals vaccinated with the recombinant OspA vaccine had an antibody response to the C6 peptide. The C6 peptide ELISA can be used to diagnose Lyme disease in patients who have received the OspA vaccine.

* Corresponding author. Mailing address: Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bldg. 10, Room 11N228, 10 Center Dr., Bethesda, MD 20892-1888. Phone: (301) 435-7668. Fax: (301) 480-0050. E-mail: amarques{at}niaid.nih.gov.

Journal of Clinical Microbiology, July 2002, p. 2591-2593, Vol. 40, No. 7
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.7.2591-2593.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ledue, T. B., Collins, M. F., Young, J., Schriefer, M. E. (2008). Evaluation of the Recombinant VlsE-Based Liaison Chemiluminescence Immunoassay for Detection of Borrelia burgdorferi and Diagnosis of Lyme Disease. CVI 15: 1796-1804 [Abstract] [Full Text]  
  • Philipp, M. T., Wormser, G. P., Marques, A. R., Bittker, S., Martin, D. S., Nowakowski, J., Dally, L. G. (2005). A Decline in C6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis. CVI 12: 1069-1074 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»